Bioinformatics Services Market Worth $4.1 Billion By 2024

Global bioinformatics services market is anticipated to reach USD 4.1 billion by 2024, according to a new report by Grand View Research, Inc. Growing adoption of I.T. solutions for different studies such as cell signaling, pathway metabolism, gene-receptor interactions, and target differentiation are expected to support growth in this market over the forecast period.

Owing to the benefits associated with the use of informatic solutions for laboratory protocol generation and data management as well as analysis, these solutions are projected to witness substantial demand in the coming years.

Moreover, collaborative activities undertaken by the information technology companies with pharmaceutical companies and clinical research organizations in order to develop and update key technologies linked to cloud computing, like online data storage and visualization of computer resources are expected to enhance market potential through to 2024.

Click the link below:
http://www.grandviewresearch.com/industry-analysis/bioinformatics-services-market

Further key findings from the report suggest:

NGS is estimated to be the dominant segment with respect to the type of service served in 2015 owing to the fact that sequence-based approach of analysis can be cataloged with the structure-based approach as complementary to genomic and proteomic approaches. Advancement in the sequencing technologies such as NGS and scripting tools (Perl & Python) for sequence manipulation coupled with the reduction in prices of the sequencing platforms and market movement towards the USD 1,000 genome resulted in a larger revenue share of this segment in the discovery informatics.
Market revenue from of chemoinformatics is second only to NGS and its strong market position can be accounted for by presence of several entities operating in this segment and their involvement in the provision of lead identification, validation, assay development, lead generation, optimization, and clinical trial based informatic solutions.
Depending on the application, transcriptomics is anticipated to register the fastest growth of over 15% owing to rise in the number of projects carried out in translational research and application of RNA transcripts for studying etiology of chronic as well as acute diseases.
Academic sector, in terms of end-use for these services, is expected to witness the fastest growth through to 2024 as a result of rise in the adoption rate of these technologies in genomic, proteomic and metabolomics research programs carried out by universities research institutes. If not all, most of these programs are either backed through government funding or private corporation backing and forms a considerable part of the high R&D investment that the bioinformatics market attracts in the current scenario.
North America dominated the industry in 2015, accounting for a little 35% of total revenue. Presence of key participants operating in the region which are involved in development of novel algorithms and software in order to improve drug attrition rates which consequently increases adoption rate of computational algorithms is attributive for the largest share of North America in sector revenue. Demand for informatic services in Europe is also increasing owing to the presence of universities in Germany and UK that are involved in development of I.T. solutions for pharmaceutical research.
Asia Pacific is estimated to witness the fastest growth over the forecast period owing to the fact that government and regulatory authorities have implemented a framework to encourage R&D collaborations and framework extension. Active expansion strategies undertaken by a number of the major market entities operating in the American market in order to strengthen their position in Asia Pacific region is a factor anticipated to consequently drive growth.
Key players operating in this industry include Agilent technologies, Siegen Inc., GVK Biosciences, Accelerys Inc, Illumina Inc., DNAnexus, Life Technologies Corporation, Geneva Bioinformatic, Celera Corporation, IBM Life sciences, and Affymetrix.
These entities are adopting strategies such as collaborations with pharmaceutical and biotechnology companies in order to enhance industrial presence by providing different data management and analytical services for the purpose of drug design and therapeutic monitoring.

High Resolution Melting Analysis Market Worth $131.7 Million By 2022

Global High Resolution Melting (HRM) market is expected to reach USD 131.7 billion by 2022 according to a new report by Grand View Research Inc.

Increasing incidences of cancer, sickle cell anemia, HIV and other STDs are expected to positively reinforce demand for smart and simple molecular diagnostics. According to the Genetic and Rare Diseases Center (GARD) in 2014, 10% of the U.S. population that is nearly 30 million people were suffering from genetic disorders. Some key disease statistics are reported below:

As per the estimates provided by CDC, number of acute cases of hepatitis C reported in the United States increased from 1,778 to 2,138 from 2012 to2013
According to the UNAIDS report, out of the 36.9 million people that are suffering with HIV/AIDS, 17.1 million are unaware about disease occurrence due to unavailability of testing services
As per the WHO estimates in 2015, there are over 130-150 million people suffering with HCV globally

Based on analyzing the disease trends and relatively lower treatment rates suggests that the demand for gene mutation and other genomic tests are expected to increase significantly over the next few years. Recent developments in the field of QPCR, next generation sequencing, genomics and big data analytics have been instrumental in strengthening the precision medicine approach. The U.S. FDA has already approved some of the treatments which are designed to meet the requirements of a specific genetic makeup or the genomic profile of the patient’s tumor.

For instance, the U.S FDA has approved a new treatment for cystic fibrosis (CF) in January, 2012. The drug kalydeco was approved for patients reported to have a specific genetic mutation known as “G551D mutation. The number of mutations which can lead to CF is in hundreds, and the G551D mutation is responsible for nearly 4% of the cases in the U.S.

Furthermore, in 2015, the Obama administration has announced the Precision Medicine Initiative with an investment of USD 216 million in the 2016 president’s budget. This initiative is expected to positively reinforce the HRM analysis market over the forecast period.

Click the link below:
http://www.grandviewresearch.com/industry-analysis/high-resolution-melting-analysis-market

Further key findings from the study suggest:

In 2014, North America dominated the overall HRM analysis market with a share of nearly 42%. Key factors attributed are high disease prevalence rates, presence of large number of academic universities; strong pharmaceutical and biotech industry, presence of large number genetic testing centers, and rapid adoption of novel technologies for improving the healthcare outcomes.
Asia pacific is identified as the fastest growing region over the forecast period. Key reasons attributed are increasing public and private expenditure on molecular diagnostics and genetic testing, increasing prevalence of genetic disorders, and increasing burden of chronic diseases such as cancer, COPD, HIV and others.
Key market players in the High Resolution Melting analysis market include, Roche Molecular Systems, Idaho Technology Corporation, Kapa Biosystems, Thermo Fisher Scientific, Premier Biosoft and Qiagen. Furthermore, Roche Molecular Systems leads the industry with the highest R&D expenditure and commands a significant market share.

Transcriptomics Technologies Market Worth $6.9 Billion By 2022

The global transcriptomics technologies market is expected to reach USD 6.9 billion by 2022, according to a new report by Grand View Research Inc. The increasing demand for genetic identification and growing investment in R&D innovation along with the technological advancements across the product portfolio are the vital driving forces of this market. The increasing R&D investments are expected to highly influence biotechnological research and develop commercialization over the forecast period. The rising investment is further anticipated to ensure positive growth and enhance business opportunities for pharmaceutical and biotechnological companies.

Furthermore, the rising demand for efficient diagnostic methods drives the need for personalized medicines. Transcriptomics tools and the offered services identify potential drug targets, which are effective methods for diagnostic methodologies. The shifting preference of pharmaceutical companies towards therapeutics results in rising demand for disease-specific biomarker identification. This change ensures a potential opportunity in the commercialization of transcriptome research results. The escalating demand for efficient diagnostics and treatment measures in the areas of oncology, HIV, Alzheimer’s disease, etc., also contributes significantly towards transcriptomics technologies market growth.

Click the link below:
http://www.grandviewresearch.com/industry-analysis/transcriptomics-technologies-market

Further key findings from the report suggest:

Polymerase Chain Reaction (PCR) based transcriptomics technologies market is expected to account for over 40% market share by 2022 owing to its ability to enable amplification even from very small amounts of genetic material samples
Next-generation Sequencing based transcriptomics technologies market is expected to grow at a lucrative CAGR of over 17.0% over the forecast period owing to increased outsourcing of sequencing technologies, upgrading of technology enabling the analysis of cellular transcriptome from various dimensions, and wide application areas of NGS
North America dominates the transcriptomics technologies market in terms of revenue owing to the increasing R&D activities by the biotechnology and pharmaceutical companies
North America and Asia Pacific are expected to witness the fastest growth of over 15.0% during the forecast period. The growth is due to the presence of untapped opportunities, rising expenditure levels, and the introduction of favorable government initiatives.
Key players of transcriptomics technologies market include Agilent Technologies, Affymetrix, Thermo Fisher Scientific, Illumina, Life Technologies, and F. Hoffmann-La Roche
Market participants are constantly engaged in strategic collaborations such as mergers and acquisitions along with technological advancements in an attempt to improve presence and ensure sustainability
For instance, in May 2015, Agilent Technologies announced the acquisition of Cartagenia that provides services and software for clinical genetic analysis. Their products are supplied to pathology laboratories and clinical research institutes. The acquisition is expected to provide higher integration and support customer satisfaction.

Cell Line Development Market To Reach $6.24 Billion By 2022

Global cell line development market size is expected to reach USD 6.24 billion by 2022, according to a new report by Grand View Research, Inc. The Increasing demand for monoclonal antibodies and patent expiration of blockbuster biologics are expected to drive the cell line development industry over the forecast period.

Increasing prevalence of autoimmune diseases and cancer are likely to increase the demand for accurate and cost effective treatment options which is expected to render a positive impact on market growth. In addition, improving healthcare infrastructure, economic development and favorable government initiatives promoting the growth of the biotechnology industry are factors contributing towards the growth of the cell line development market.

Ongoing R&D for stable & authentic cell lines and the introduction of technologically advanced processes such as single use bioreactor and micro bioreactor for large scale bioproduction are further expected to provide this market with lucrative future growth opportunities.

To request a sample copy:
http://www.grandviewresearch.com/industry-analysis/cell-line-development-market

Further key findings from the study suggest:

Reagent and media was the largest product market in 2014, owing to increasing number of cell culture procedures. Reagent and media are necessary components involved in cell line development procedures & cell culture and are cost intensive in nature. The market for reagent and media was valued at over 1.0 billion in 2014.
Mammalian cell lines were widely used as a source for cell line development in 2014, owing to associated advantages such as accurate complex protein expression nature, critical for the production of monoclonal antibodies, vaccines, and biologics.
Cell line development finds the largest application in the bioproduction of biologics, vaccines, Mabs, therapeutic proteins and biosimilars. Rising demand for monoclonal antibodies and vaccines are expected to boost the growth of this segment over the forecast period. The market for cell line development based bioproduction is also expected to witness lucrative growth of over 12.5% during the forecast period.
North America was the largest market in 2014, with revenue estimated at over 800 million. The region’s market dominance is attributed to factors such as the growing adoption rates of cell culture techniques, presence of well-developed healthcare infrastructure, supportive government initiatives and high healthcare expenditure levels.
Asia Pacific cell line development market is anticipated to register rapid growth over the forecast period owing to factors such as the presence of high unmet needs, rising number of CROs (Contract Research Organization) providing pertinent services, growing R&D investments aimed at the development of stable cell lines and increasing biologics production.
Key players in this market include European Collection of cell Cultures (ECACC), Lonza Group AG, GE Healthcare, Thermo Fisher Scientific Inc., Sartorious AG, Selexis SA, Wuxi AppTec Inc., Sigma-Aldrich Corporation, American Type Culture Collection (ATCC) and Corning Inc.